---
input_text: 'Huntington Disease: Linking Pathogenesis to the Development of Experimental
  Therapeutics. Huntington disease (HD) is an autosomal dominant neurodegenerative
  condition caused by a CAG trinucleotide expansion in the huntingtin gene. At present,
  the HD field is experiencing exciting times with the assessment for the first time
  in human subjects of interventions aimed at core disease mechanisms. Out of a portfolio
  of interventions that claim a potential disease-modifying effect in HD, the target
  huntingtin has more robust validation. In this review, we discuss the spectrum of
  huntingtin-lowering therapies that are currently being considered. We provide a
  critical appraisal of the validation of huntingtin as a drug target, describing
  the advantages, challenges, and limitations of the proposed therapeutic interventions.
  The development of these new therapies relies strongly on the knowledge of HD pathogenesis
  and the ability to translate this knowledge into validated pharmacodynamic biomarkers.
  Altogether, the goal is to support a rational drug development that is ethical and
  cost-effective. Among the pharmacodynamic biomarkers under development, the quantification
  of mutant huntingtin in the cerebral spinal fluid and PET imaging targeting huntingtin
  or phosphodiesterase 10A deserve special attention. Huntingtin-lowering therapeutics
  are eagerly awaited as the first interventions that may be able to change the course
  of HD in a meaningful way.'
raw_completion_output: |-
  primary_disease: Huntington Disease

  medical_actions: assessment of interventions; huntingtin-lowering therapies; quantification of mutant huntingtin in the cerebral spinal fluid; PET imaging targeting huntingtin or phosphodiesterase 10A

  symptoms: 

  chemicals: 

  action_annotation_relationships: huntingtin-lowering therapies TREATS Huntington Disease; quantification of mutant huntingtin in the cerebral spinal fluid TREATS Huntington Disease; PET imaging targeting huntingtin or phosphodiesterase 10A TREATS Huntington Disease
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  PET imaging targeting huntingtin or phosphodiesterase 10A TREATS Huntington Disease

  ===

extracted_object:
  primary_disease: MONDO:0007739
  medical_actions:
    - assessment of interventions
    - huntingtin-lowering therapies
    - quantification of mutant huntingtin in the cerebral spinal fluid
    - PET imaging targeting huntingtin or phosphodiesterase 10A
  action_annotation_relationships:
    - subject: huntingtin-lowering therapies
      predicate: TREATS
      object: Huntington Disease
    - subject: <quantification of mutant huntingtin in the cerebral spinal fluid>
      predicate: <TREATS>
      object: <Huntington Disease>
      qualifier: <>
      subject_qualifier: <>
      object_qualifier: <>
      subject_extension: <mutant huntingtin>
      object_extension: <>
    - subject: <PET imaging>
      predicate: <TREATS>
      object: <Huntington Disease>
      qualifier: <Huntington Disease>
      subject_qualifier: <targeting huntingtin or phosphodiesterase 10A>
      object_qualifier: <>
      subject_extension: <huntingtin, phosphodiesterase 10A>
      object_extension: <>
named_entities:
  - id: MONDO:0007739
    label: Huntington disease (HD)
  - id: HP:0001268
    label: Cognitive decline
  - id: CHEBI:76720
    label: Antisense oligonucleotides
  - id: HP:0002180
    label: neurodegeneration
  - id: MAXO:0001001
    label: gene therapies
  - id: MAXO:0000882
    label: Behavioral interventions
  - id: HP:0002315
    label: headache
  - id: CHEBI:134738
    label: laquinimod
  - id: CHEBI:4903
    label: ethinylestradiol
  - id: CHEBI:6443
    label: levonorgestrel
  - id: MONDO:0002602
    label: Central nervous system disorders
  - id: CHEBI:3962
    label: Curcumin
  - id: CHEBI:50803
    label: nanoparticles
  - id: MONDO:0005071
    label: Neurological Disorders
  - id: MAXO:0000647
    label: Chemotherapy
  - id: HP:0100543
    label: Cognitive impairment
  - id: HP:0012174
    label: glioblastoma
  - id: MONDO:0005109
    label: HIV
  - id: MONDO:0005559
    label: Neurodegenerative diseases
  - id: CHEBI:16243
    label: quercetin
  - id: CHEBI:27881
    label: resveratrol
  - id: CHEBI:75095
    label: chrysin
  - id: CHEBI:28821
    label: piperine
  - id: CHEBI:17620
    label: ferulic acid
  - id: CHEBI:78330
    label: huperzine A
  - id: CHEBI:16118
    label: berberine
  - id: CHEBI:2979
    label: baicalein
  - id: CHEBI:28230
    label: hesperetin
  - id: CHEBI:26536
    label: retinoic acid
  - id: HP:0000708
    label: Behavioral symptoms
  - id: MAXO:0001298
    label: therapy
  - id: MAXO:0009003
    label: Preimplantation genetic testing (PGT-M)
  - id: MONDO:0016621
    label: Juvenile Huntington Disease
  - id: HP:0000709
    label: psychosis
  - id: HP:0011951
    label: aspiration pneumonia
  - id: HP:0000716
    label: depression
  - id: MAXO:0000065
    label: aerobic exercises
  - id: MAXO:0000487
    label: clinical assessments
  - id: MAXO:0000387
    label: muscle biopsy
  - id: HP:0012531
    label: pain
  - id: HP:0100021
    label: Cerebral palsy
  - id: HP:0001915
    label: Aplastic anemia
  - id: HP:0002072
    label: Chorea
  - id: CHEBI:9467
    label: Tetrabenazine
  - id: MAXO:0000011
    label: Physical therapy
  - id: HP:0000739
    label: anxiety
  - id: CHEBI:7872
    label: oxytocin
  - id: CHEBI:9937
    label: vasopressin
  - id: HP:0033429
    label: neuroinflammation
  - id: MAXO:0000079
    label: genetic counseling
  - id: CHEBI:149681
    label: computer adaptive test (CAT)
  - id: MAXO:0000016
    label: Cell Therapy
  - id: MONDO:0005314
    label: Relapsing-remitting multiple sclerosis (RRMS)
  - id: HP:0011227
    label: elevated CRP
  - id: HP:0005268
    label: Spontaneous abortion
  - id: MAXO:0000021
    label: Palliative care
  - id: CHEBI:16348
    label: 3-nitropropionic acid (3-NP)
  - id: MAXO:0000068
    label: Transplantation
  - id: HP:0002344
    label: Progressive neurodegeneration
  - id: MONDO:0008199
    label: Parkinson disease (PD)
  - id: HP:0002527
    label: falls
  - id: CHEBI:25016
    label: Phosphate-buffered saline (PBS)
  - id: CHEBI:33385
    label: Tyrosine Hydroxylase (TH)
  - id: HP:0000657
    label: Ocular Motor Apraxia
  - id: HP:0025464
    label: Oxidative stress
  - id: HP:0003287
    label: Mitochondrial dysfunction
  - id: HP:0002511
    label: Alzheimer's disease
  - id: HP:0040141
    label: Tardive dyskinesia
  - id: HP:0001297
    label: Stroke
  - id: HP:0000618
    label: Blindness
  - id: HP:0001658
    label: Myocardial infarction
  - id: HP:0001824
    label: weight loss
  - id: CHEBI:27314
    label: water-soluble vitamins
  - id: CHEBI:46662
    label: minerals
  - id: HP:0002446
    label: Astrogliosis
  - id: HP:0000737
    label: Irritability
  - id: HP:0000741
    label: Apathy
